Connor, Clark & Lunn Investment Management Ltd.

Position in NAGE — Niagen Bioscience, Inc.

CIK 1596800 VANCOUVER, A1

Position in NAGE

as of Mar 31, 2026 · filed May 11, 2026 Compact

Position Value

$2,568,595

-$1,147,101 QoQ

Shares Held

582,448

-0.3% QoQ

Ownership

0.731%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Jun 2023

12 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Mar 31, 2026

Connor, Clark & Lunn Investment Management Ltd. holds $703,286,486 across 100 Biotechnology names. NAGE ranks #51 (0.4% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	251,711	$112,399,029
2	IONS	Ionis Pharmaceuticals Inc	874,089	$65,635,343
3	ARWR	Arrowhead Pharmaceuticals, Inc.	836,981	$52,478,708
4	MIRM	Mirum Pharmaceuticals, Inc.	479,476	$44,293,992
5	REGN	Regeneron Pharmaceuticals, Inc.	32,164	$24,851,192
6	AXSM	Axsome Therapeutics, Inc.	134,792	$22,782,543
7	SRPT	Sarepta Therapeutics, Inc.	1,019,951	$22,194,133
8	TERN	Terns Pharmaceuticals, Inc.	384,681	$20,280,382

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$2,568,595	582,448	-0.3%	Shares	Sole	2026-05-11
2025-12-31	$3,715,696	584,229	-7.0%	Shares	Sole	2026-02-10
2025-09-30	$5,858,111	627,879	-23.7%	Shares	Sole	2025-11-13
2025-06-30	$11,864,113	823,325	+10.6%	Shares	Sole	2025-08-07
2025-03-31	$5,136,981	744,490	+47.1%	Shares	Sole	2025-05-12
2024-12-31	$2,687,847	506,186	+189.0%	Shares	Sole	2025-02-10
2024-09-30	$639,377	175,172	+10.8%	Shares	Sole	2024-11-08
2024-06-30	$431,495	158,057	+18.8%	Shares	Sole	2024-08-09
2024-03-31	$463,069	133,066	+14.2%	Shares	Sole	2024-05-09
2023-12-31	$166,613	116,513	+40.3%	Shares	Sole	2024-02-09
2023-09-30	$121,225	83,031	+121.9%	Shares	Sole	2023-11-13
2023-06-30	$58,738	37,413	—	Shares	Sole	2023-08-10
No filing history on record for this holder in this stock.